Top
image credit: qimono / pixabay

Study reveals investigational drug as effective treatment for relapsed marginal zone lymphoma

April 1, 2019

Category:

A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients with relapsed marginal zone lymphoma (MZL). Findings from the Phase II trial were presented by study co-lead Nathan Fowler, M.D., associate professor in the Department of Lymphoma & Myeloma, at the AACR Annual Meeting 2019 in Atlanta.

MZL is a low-grade non-Hodgkin lymphoma that accounts for 6 percent of all lymphoma diagnoses. Although it is treatable, many patients relapse, at which point few treatment options exist.

Read More on The Medical News